Turning Point Therapeutics Inc.

# Signal Note: Driehaus Initiates $52.2M Position in TPTX Driehaus's entry into Turning Point signals conviction in the company's pipeline, likely driven by repozerhansen (TPS d5023), a next-generation ROS1 inhibitor in development for ROS1+ non-small cell lung cancer with potential to overcome resistance mechanisms to first-gen agents like crizotinib. The $52.2M position sizing suggests meaningful near-term catalyst expectations, potentially including Phase 2 efficacy readouts or regulatory pathway clarity in 2024-2025. This positions Driehaus for potential upside if TPTX demonstrates clinical superiority or durability advantages over the entrenched competitive landscape.